Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B And T Cell Immunity After Donor Lymphocyte Infusion
Year: 2010
Type: article
Study design: Case Report
Abstract: Donor lymphocyte infusion (DLI) is a highly effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic hematopoietic stem cell transplantation (HSCT), in which 70-80% patients achieve curative responses. Despite its clinical efficacy, the mechanism by which DLI achieves anti-tumor immunity remains incompletely understood. CML66 is a CML-associated antigen that is preferentially expressed in myeloid progenitor cells. CML66 elicited a potent antibody response in a patient with CML who achieved complete molecular remission following CD4+DLI in the absence of graft-versus-host disease.
Institution: Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2122003293